Deidrobenzperidolo
Brand names,
Deidrobenzperidolo
Analogs
Deidrobenzperidolo
Brand Names Mixture
Deidrobenzperidolo
Chemical_Formula
C10H16NO+
Deidrobenzperidolo
RX_link
http://www.rxlist.com/cgi/generic3/edrophonium.htm
Deidrobenzperidolo
fda sheet
Deidrobenzperidolo
msds (material safety sheet)
Deidrobenzperidolo
Synthesis Reference
No information avaliable
Deidrobenzperidolo
Molecular Weight
166.24 g/mol
Deidrobenzperidolo
Melting Point
No information avaliable
Deidrobenzperidolo
H2O Solubility
Appreciable as liquid hydrochloride salt
Deidrobenzperidolo
State
Liquid
Deidrobenzperidolo
LogP
-2.95
Deidrobenzperidolo
Dosage Forms
Liquid for injection
Deidrobenzperidolo
Indication
For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.
Deidrobenzperidolo
Pharmacology
Edrophonium is a short and rapid-acting anticholinesterase drug. Its effect is manifest within 30 to 60 seconds after injection and lasts an average of 10 minutes. Edrophonium's pharmacologic action is due primarily to the inhibition or inactivation of acetylcholinesterase at sites of cholinergic transmission. Muscarinic receptors are found throughout the body, especially on muscle. Stimulation of these receptors causes to muscle contraction. In myasthenia gravis the body's immune system destroys many of the muscarinic receptors, so that the muscle becomes less responsive to nervous stimulation. Edrophonium chloride increases the amount of acetylcholine at the nerve endings. Increased levels of acetyl choline allow the remaining receptors to function more efficiently.
Deidrobenzperidolo
Absorption
Rapidly absorbed.
Deidrobenzperidolo
side effects and Toxicity
With drugs of this type, muscarine-like symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions and bradycardia) often appear with overdosage (cholinergic crisis).
Deidrobenzperidolo
Patient Information
No information avaliable
Deidrobenzperidolo
Organisms Affected
Humans and other mammals